// App-Quantinova.ai

2061 : Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.

Researchers

Presenter

  • Annick Desjardins

Principal Investigators

  • John H. Sampson

  • Katherine B. Peters

  • Gordana Vlahovic

  • Dina Randazzo

  • Stevie Threatt

  • James Emmett Herndon

  • Susan Boulton

  • Denise Lally-Goss

  • Frances McSherry

  • Eric S Lipp

  • Allan H. Friedman

  • Henry S. Friedman

  • Darell D. Bigner

  • Matthias Gromeier

Medical Centers

  • Duke University Medical Center, Durham, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gliomas

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT01491893

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved